ClinicalTrials.gg
CompletedNCT01907854LIRA-SWITCH™Updated Oct 2, 2018Results posted

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

A Phase 4 interventional study of liraglutide and sitagliptin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 106 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
407
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
27th of 151
407 · median 62
Started
2013
with 17 others
Phase 4
48 of 151
1 open now
Registered
79th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 18 that started in 2013, is one of 48 in phase 4, and was the 79th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 407 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
    • Subjects diagnosed with type 2 diabetes and treated with metformin equal to or above 1500 mg/day (or maximum tolerated dose equal to or above 1000 mg/day) and sitagliptin 100 mg/day, both at a stable dose for at least 90 days prior to screening. Stable is defined as unchanged medication and dose
    • 7.5% - 9.5% (58 mmol/mol - 80 mmol/mol) (both inclusive)
    • equal to or above 20 kg/m\^2

Exclusion criteria

Exclusion Criteria:

    • Any chronic disorder or severe disease which at the discretion of the investigator might jeopardise subject's safety or compliance with the protocol
    • Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days prior to screening. An exception is short-term treatment (equal to or less than 7 days in total) with insulin in connection with intercurrent illness
    • Female who is pregnant, breast-feeding, intends to become pregnant or of not using adequate methods (adequate contraceptive measures as required by local regulations or practice)
    • History of chronic pancreatitis or idiopathic acute pancreatitis
    • Screening calcitonin value equal to or above 50 ng/L
    • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
    • Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
    • Impaired liver function, defined as equal to or above 2.5 times upper normal limit
    • Impaired renal function defined as estimated 60 mL/min/1.73 m\^2 per modification of diet in renal disease formula
    • Any episode of unstable angina, acute coronary event, cerebral stroke/ or other significant cardiovascular event as judged by the investigator within 90 days prior to screening
    • Heart failure, class IV
    • Uncontrolled treated or untreated hypertension (systolic blood pressure equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    Liraglutide + metformin + sitagliptin placebo

    Drug: liraglutide · Drug: placebo

  • Experimental
    Sitagliptin + metformin + liraglutide placebo

    Drug: sitagliptin · Drug: placebo

Interventions

  • Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)

  • 100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)

  • Drugplacebo

    Sitagliptin placebo tablets once-daily

  • Drugplacebo

    Sitagliptin placebo tablets once-daily

07

What researchers measure

Primary outcomes

  1. Change in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c was analysed after 26 weeks of treatment. Analysis population set: full analysis set (FAS); all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using mixed model for repeated measurements (MMRM).

    Time frame: From baseline to week 26

Secondary outcomes

  1. Change in Body Weight

    Change from baseline in body weight was analysed after 26 weeks of treatment. Analysis population set: FAS: all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using MMRM.

    Time frame: From baseline to week 26

  2. Change in Fasting Plasma Glucose

    Change from baseline in fasting plasma glucose was analysed after 26 weeks of treatment. Missing values were imputed using MMRM.

    Time frame: From baseline to week 26

  3. Change in Fasting Blood Lipids

    Ratio to baseline in fasting blood lipids (total cholesterol, low density lipoprotein \[LDL\], very low density lipoprotein \[VLDL\], high density lipoprotein \[HDL\], triglycerides, and free fatty acids) were analysed after 26 weeks treatment. Missing values were imputed using MMRM. Here we are presenting ratio to baseline data.

    Time frame: From baseline to week 26

  4. Change in Systolic Blood Pressure and Diastolic Blood Pressure

    Change from baseline in systolic and diastolic blood pressure were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.

    Time frame: From baseline to week 26

  5. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association Target) (y/n)

    Number of subjects who achieve HbA1c \<7.0% were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.

    Time frame: After 26 weeks of treatment

  6. Number of Treatment Emergent Adverse Events (TEAEs)

    A treatment emergent adverse event (TEAE) was defined as an event that had an onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. The number of TEAEs was recorded during 26 weeks of treatment plus one week follow-up period.

    Time frame: During 26 weeks of treatment plus one week follow-up period.

08

Results

Posted Jul 1, 2016

Participant flow

The trial was conducted at 86 sites in 6 countries: Canada (14); Hungary (8); India (7); Israel (8); Spain (6); and United States (43).

Participant flow — Overall Study
MilestoneLiraglutideSitagliptin
Started203204
Exposed202204
Completed187191
Not completed1613
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject97
Withdrew: Lost to follow-up22
Withdrew: Unclassified43

Outcome measures

PrimaryChange in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c was analysed after 26 weeks of treatment. Analysis population set: full analysis set (FAS); all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using mixed model for repeated measurements (MMRM).

Time frame:
From baseline to week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in HbA1c (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinLiraglutideSitagliptin
Change in HbA1c (Glycosylated Haemoglobin)-1.146 ± 0.9748-0.529 ± 1.0148
Statistical analysis
  • Liraglutide vs Sitagliptin · Mixed Models Analysis · p = <0.0001 · Treatment difference: -0.61 · 95% CI -0.82 to -0.40Superiority of liraglutide over sitagliptin was concluded if the 95% Confidence Interval for the treatment difference was entirely below 0%.
SecondaryChange in Body Weight

Change from baseline in body weight was analysed after 26 weeks of treatment. Analysis population set: FAS: all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using MMRM.

Time frame:
From baseline to week 26
Reported as:
Mean · kg
Change in Body Weight
kgLiraglutideSitagliptin
Change in Body Weight-3.32 ± 3.135-1.80 ± 2.974
Statistical analysis
  • Liraglutide vs Sitagliptin · Mixed Models Analysis · p = <0.0001 · Treatment difference: -1.67 · 95% CI -2.34 to -0.99Superiority of liraglutide over sitagliptin was concluded if the 95% Confidence Interval for the treatment difference was entirely below 0%.
SecondaryChange in Fasting Plasma Glucose

Change from baseline in fasting plasma glucose was analysed after 26 weeks of treatment. Missing values were imputed using MMRM.

Time frame:
From baseline to week 26
Reported as:
Mean · nmol/L
Change in Fasting Plasma Glucose
nmol/LLiraglutideSitagliptin
Change in Fasting Plasma Glucose-1.967 ± 2.3585-0.588 ± 2.1363
SecondaryChange in Fasting Blood Lipids

Ratio to baseline in fasting blood lipids (total cholesterol, low density lipoprotein \[LDL\], very low density lipoprotein \[VLDL\], high density lipoprotein \[HDL\], triglycerides, and free fatty acids) were analysed after 26 weeks treatment. Missing values were imputed using MMRM. Here we are presenting ratio to baseline data.

Time frame:
From baseline to week 26
Reported as:
Mean · ratio
Change in Fasting Blood Lipids
ratioLiraglutideSitagliptin
Total cholesterol1.011 ± 0.19061.045 ± 0.2323
LDL cholesterol1.049 ± 0.38991.121 ± 0.4661
VLDL cholesterol1.062 ± 0.42361.075 ± 0.4625
HDL cholesterol1.004 ± 0.15280.997 ± 0.1548
Triglycerides1.089 ± 0.49751.099 ± 0.4889
Free Fatty acids1.086 ± 0.7741.104 ± 0.5839
SecondaryChange in Systolic Blood Pressure and Diastolic Blood Pressure

Change from baseline in systolic and diastolic blood pressure were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.

Time frame:
From baseline to week 26
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure and Diastolic Blood Pressure
mmHgLiraglutideSitagliptin
Systolic Blood Pressure-3.6 ± 11.596-2.57 ± 11.593
Diastolic Blood Pressure-0.23 ± 7.085-0.81 ± 7.193
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association Target) (y/n)

Number of subjects who achieve HbA1c \<7.0% were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.

Time frame:
After 26 weeks of treatment
Reported as:
Number · percentage (%)
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association Target) (y/n)
percentage (%)LiraglutideSitagliptin
Yes50.626.9
No49.473.1
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

A treatment emergent adverse event (TEAE) was defined as an event that had an onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. The number of TEAEs was recorded during 26 weeks of treatment plus one week follow-up period.

Time frame:
During 26 weeks of treatment plus one week follow-up period.
Reported as:
Number · number of events
Number of Treatment Emergent Adverse Events (TEAEs)
number of eventsLiraglutideSitagliptin
Number of Treatment Emergent Adverse Events (TEAEs)455318

Adverse events

Collected over 27 weeks (26 weeks of treatment period + 1 week of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide—6/202 (3%)96/202 (47.5%)
Sitagliptin—7/204 (3.4%)61/204 (29.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLiraglutideSitagliptin
FallInjury, poisoning and procedural complications2/2020/204
Acute coronary syndromeCardiac disorders1/2020/204
Cardiac failure congestiveCardiac disorders1/2020/204
Prinzmetal anginaCardiac disorders1/2020/204
PneumoniaInfections and infestations1/2021/204
DepressionPsychiatric disorders1/2020/204
Joint arthroplastySurgical and medical procedures1/2020/204
Myocardial ischaemiaCardiac disorders0/2021/204
Non-cardiac chest painGeneral disorders0/2021/204
Pneumococcal sepsisInfections and infestations0/2021/204
Most frequent other events
Most frequent other events
EventLiraglutideSitagliptin
NauseaGastrointestinal disorders44/20216/204
DiarrhoeaGastrointestinal disorders33/20219/204
Decreased appetiteMetabolism and nutrition disorders18/2027/204
VomitingGastrointestinal disorders15/20210/204
HeadacheNervous system disorders13/20212/204
Upper respiratory tract infectionInfections and infestations12/20213/204
NasopharyngitisInfections and infestations12/2027/204
Lipase increasedInvestigations11/2029/204

Baseline characteristics

Demographics and baseline characteristics of all exposed subjects are summarised in continuous variables. There were missing baseline values for fasting plasma glucose in 2 subjects in the liraglutide arm and 1 subject in the sitagliptin arm.

Age, Continuous
Age, Continuous(years)LiraglutideSitagliptinTotal
Mean56.3 ± 10.656.5 ± 9.756.4 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)LiraglutideSitagliptinTotal
Female8579164
Male117125242
HbA1c
HbA1c(percentage of glycosylated haemoglobin)LiraglutideSitagliptinTotal
Mean8.3 ± 0.68.2 ± 0.68.3 ± 0.6
Body Weight
Body Weight(kg)LiraglutideSitagliptinTotal
Mean88.9 ± 19.891.2 ± 19.690.1 ± 19.7
Fasting Plasma Glucose
Fasting Plasma Glucose(mmol/L)LiraglutideSitagliptinTotal
Mean10.0 ± 2.79.7 ± 2.59.9 ± 2.6
09

Study locations

106 sites
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85018, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85027, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85704, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85724, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Mission Viejo, California 92691, United States
  • Novo Nordisk Investigational Site
    Roseville, California 95661, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80922, United States
  • Novo Nordisk Investigational Site
    Chiefland, Florida 32626, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33183, United States
  • Novo Nordisk Investigational Site
    North Miami, Florida 33181, United States
  • Novo Nordisk Investigational Site
    Port Charlotte, Florida 33952, United States
  • Novo Nordisk Investigational Site
    Johns Creek, Georgia 30097, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Blackfoot, Idaho 83221, United States
  • Novo Nordisk Investigational Site
    Arlington Heights, Illinois 60005-4144, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60604, United States
  • Novo Nordisk Investigational Site
    Peoria, Illinois 61602, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Avon, Indiana 46123, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47725, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    Bangor, Maine 04401, United States
  • Novo Nordisk Investigational Site
    Fall River, Massachusetts 02720, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48085-5524, United States
  • Novo Nordisk Investigational Site
    Saint Peters, Missouri 63376, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89119, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Berlin, New Jersey 08009, United States
  • Novo Nordisk Investigational Site
    Elizabeth, New Jersey 07202, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28210, United States
  • Novo Nordisk Investigational Site
    Salisbury, North Carolina 28144, United States
  • Novo Nordisk Investigational Site
    Akron, Ohio 44311, United States
  • Novo Nordisk Investigational Site
    Reading, Pennsylvania 19606, United States
  • Novo Nordisk Investigational Site
    Moncks Corner, South Carolina 29461, United States
  • Novo Nordisk Investigational Site
    Orangeburg, South Carolina 29118, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119, United States
  • Novo Nordisk Investigational Site
    Edinburg, Texas 78539, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76104, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77024, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77036, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77079, United States
  • Novo Nordisk Investigational Site
    Midland, Texas 79707, United States
  • Novo Nordisk Investigational Site
    New Braunfels, Texas 78130, United States
  • Novo Nordisk Investigational Site
    North Richland Hills, Texas 76180, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78245, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Virginia Beach, Virginia 23454, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99202-3649, United States
  • Novo Nordisk Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • Novo Nordisk Investigational Site
    Brampton, Ontario L6S 0C6, Canada
  • Novo Nordisk Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Novo Nordisk Investigational Site
    Concord, Ontario L4K 4M2, Canada
  • Novo Nordisk Investigational Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Novo Nordisk Investigational Site
    Grimsby, Ontario L3M 1P3, Canada
  • Novo Nordisk Investigational Site
    Ottawa, Ontario K1K 4L2, Canada
  • Novo Nordisk Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Novo Nordisk Investigational Site
    Strathroy, Ontario N7G 1Y7, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M3J 1N2, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4G 3E8, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M9V 4B4, Canada
  • Novo Nordisk Investigational Site
    Drummondville, Quebec J2B 7T1, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H4A 3T2, Canada
  • Novo Nordisk Investigational Site
    St. Romuald, Quebec G6W 5M6, Canada
  • Novo Nordisk Investigational Site
    Trois Rivières, Quebec G8T 7A1, Canada
  • Novo Nordisk Investigational Site
    Quebec, G3K 2P8, Canada
  • Novo Nordisk Investigational Site
    Budapest, 1042, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4043, Hungary
  • Novo Nordisk Investigational Site
    Eger, 3300, Hungary
  • Novo Nordisk Investigational Site
    Gyula, H-5700, Hungary
  • Novo Nordisk Investigational Site
    Salgótarján, 3100, Hungary
  • Novo Nordisk Investigational Site
    Sopron, 9400, Hungary
  • Novo Nordisk Investigational Site
    Szeged, H-6720, Hungary
  • Novo Nordisk Investigational Site
    Tatabánya, 2800, Hungary
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500082, India
  • Novo Nordisk Investigational Site
    Visakhapatnam, Andhra Pradesh 530002, India
  • Novo Nordisk Investigational Site
    Ahmedabad, Gujarat 380008, India
  • Novo Nordisk Investigational Site
    Gandhinagar, Gujarat 382428, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560002, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400007, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411040, India
  • Novo Nordisk Investigational Site
    New Delhi, 110060, India
  • Novo Nordisk Investigational Site
    Haifa, 3339419, Israel
  • Novo Nordisk Investigational Site
    Haifa, 35152, Israel
  • Novo Nordisk Investigational Site
    Herzliya, 46851, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Nahariya, 22100, Israel
  • Novo Nordisk Investigational Site
    Ofakim, 87520, Israel
  • Novo Nordisk Investigational Site
    Tel Aviv, 6937947, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 62038, Israel
  • Novo Nordisk Investigational Site
    San Juan, 00921, Puerto Rico

Showing the first 100 of 106 sites across 7 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Bailey TS, Takacs R, Tinahones FJ, Rao PV, Tsoukas GM, Thomsen AB, Kaltoft MS, Maislos M. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016 Dec;18(12):1191-1198. doi: 10.1111/dom.12736. Epub 2016 Sep 14. PubMed 27381275 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Jun 2015, 18 months.

Results were first posted in Jul 2016, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 18 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Jul 25, 2013
StartActual
Dec 2, 2013
Primary completionActual
Jun 15, 2015
CompletionActual
Jun 15, 2015
Results first posted
Jul 1, 2016
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01907854
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 25, 2013
Start date
Dec 2, 2013
Primary completion
Jun 15, 2015
Completion
Jun 15, 2015
Results posted
Jul 1, 2016
Last update
Oct 2, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liraglutide · Sitagliptin

Start the discussion